Letrozole Stems Breast Ca Return After Tamoxifen

Use of the aromatase inhibitor letrozole was linked to a significant 63% reduction in disease recurrence in women with early-stage breast cancer who completed 5 years of tamoxifen therapy 1 to 7 years earlier, results of a phase III study suggest.